Analysis of drug resistance-associated proteins expressions of patients with the recurrent of acute leukemia via protein microarray technology

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 4, 2014, Pages 537-543

  Zeng, D F ^a   Zhang, J ^a   Zhu, L D ^a   Kong, P Y ^a   Li, J P ^a   Zhang, Xi ^a   Xu, W ^a   Wang, J L ^a   Pen, X G ^a   Wang, P ^a   Liu, S H ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute leukemia; Multidrug resistance; Prognosis; Protein microarray; Recurrent

Indexed keywords

ARSENIC TRIOXIDE; ASPARAGINASE; CHEMOKINE RECEPTOR CXCR4; CYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; GLUTATHIONE TRANSFERASE P1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PREDNISONE; PROTEIN BCL 2; RETINOIC ACID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; TUMOR MARKER; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MALE; MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; TECHNOLOGY; CASE CONTROL STUDY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM PROTEINS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84897008093     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. PUI C-H, CHENG C, LEUNG W, RAI SN, RIVERA GK, SANDLUND JT, RIBEIRO RC, RELLING MV, KUN LE, EVANS WE. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 2003; 349: 640-649.
2. BELSON M, KINGSLEY B, HOLMES A. Risk factors for acute leukemia in children: a review. Environ Health Perspect 2007; 115: 138.
3. HERSH EM, WHITECAR JR JP, MCCREDIE KB, BODEY SR GP, FREIREICH EJ. Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med 1971; 285: 1211.
4. OLSON DP, TAYLOR BJ, LA M, SATHER H, REAMAN GH, IVY SP. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology Group. Leuk Lymphoma 2005; 46: 681-691.
5. MCKENNA SL, PADUA RA. Multidrug resistance in leukaemia. Br J Haematol 1997; 96: 659-674.
6. DE SOUZA R, ZAHEDI P, BADAME RM, ALLEN C, PIQUETTE-MILLER M. Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. Mol Cancer Ther 2011; 10: 1289-1299.
7. VARMA MV, ASHOKRAJ Y, DEY CS, PANCHAGNULA R. Pglycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003; 48: 347-359.
8. SHI H, LU D, SHU Y, SHI W, LU S, WANG K. Expression of multidrug resistance-related proteins p-glycoproteinglutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest 2008; 26: 344-351.
9. MEIJER G, SCHROEIJERS A, FLENS M, MEUWISSEN S, VAN DER VALK P, BAAK J, SCHEPER R. Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis. J Clin Pathol 1999; 52: 450-454.
10. AFSAR NA, HAENISCH S, MATEEN A, USMAN A, UFER M, AHMED KZ, AHMAD HR, CASCORBI I. Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. Basic Clin Pharmacol Toxicol 2010; 107: 570-576.
11. VON EGGELING F, DAVIES H, LOMAS L, FIEDLER W, JUNKER K, CLAUSSEN U, ERNST G. Tissue-specific microdissection coupled with ProteinChip® array technologies: applications in cancer research. Biotechniques 2000; 29: 1066-1071.
12. ZHU H, SNYDER M. Protein chip technology. Curr Opin Chem Biol 2003; 7: 55-63.
13. HARTMANN M, ROERAADE J, STOLL D, TEMPLIN MF, JOOS TO. Protein microarrays for diagnostic assays. Analyt Bioanalyt Chem 2009; 393: 1407-1416.
14. BENNETT JM, CATOVSKY D, DANIEL MT, FLANDRIN G, GALTON DA, GRALNICK HR, SULTAN C. Proposed revised criteria for the classification of acute myeloid leukemia A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
15. ZHANG Z. Blood diseases diagnosis and treatment standards. Beijing: Science Press, 2007.
16. FERRARA F, PALMIERI S, LEONI F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 2008; 66: 181-193.
17. PUI CH RL, LOOK AT. Acute Lymphoblastic Leukemia. Lancet 2008; 371: 1030-1043.
18. PUI C-H. Acute lymphoblastic leukemia. Pediatr Clin N Am 1997; 44: 831-846.
19. FLOHR T, SCHRAUDER A, CAZZANIGA G, PANZER-GRÜMAYER R, VAN DER VELDEN V, FISCHER S, STANULLA M, BASSO G, NIGGLI F, SCHÄFER B. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782.
20. BASSAN R, HOELZER D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 532-543.
21. KODADEK T. Protein microarrays:prospects and problems. Chem Biol 2001; 8: 105-115.
22. LEUKEMIAS SCGO. Expressions of P-gp, mdr1, MRP and Topo π in acute leukemia patients and their correlation with prognosis. Chinese J Hematol 2001; 22: 90-93.
23. SHMAN T, SAVITSKII V, POTAPNEV M, ALEINIKOVA O. Study of expression and functional activity of PGP membrane glycoprotein in children with acute leukemia. Bull Exp Biol Med 2006; 141: 727-730.
24. BAUMERT C, HILGEROTH A. Recent advances in the development of P-gp inhibitors. Anticancer Agents Med Chem 2009; 9: 415-436.
25. VALERA ET, SCRIDELI CA, QUEIROZ R, MORI B, TONE LG. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J 2004; 122: 166-171.
26. DE FIGUEIREDO-PONTES LL, PINTÃO MCT, OLIVEIRA LC, DALMAZZO LF, JÁCOMO RH, GARCIA AB, FALCAO RP, REGO EM. Determination of P-glycoprotein, MDRrelated protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin Cytom 2008; 74: 163-168.
27. GURBUXANI S, SINGH ARYA L, RAINA V, SAZAWAL S, KHATTAR A, MAGRATH I, MARIE J-P, BHARGAVA M. Significance of MDR1, MRP1, GSTπ and GSTμ mRNA expression in acute lymphoblastic leukemia in Indian patients. Cancer Lett 2001; 167: 73-83.
28. VOSO MT, HOHAUS S, GUIDI F, FABIANI E, D'ALÒ F, GRONER S, SPÄTH D, DOEHNER K, LEONE G, DOEHNER H. Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia 2008; 22: 1685-1691.
29. AMIRGHOFRAN Z, DANESHBOD Y, GHOLIJANI N. Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome. Oncology Res Featuring PreClin Clin Cancer Ther 2009; 17: 447-454.
30. PALISSOT V, MORJANI H, BELLOC F, COTTERET S, DUFER J, BERCHEM G. From molecular characteristics to cellular events in apoptosis-resistant HL-60 cells. Int J Oncol 2005; 26: 825-834.
31. CHIKAMORI K, HILL J, GRABOWSKI D, ZARKHIN E, GROZAV A, VAZIRI S, WANG J, GUDKOV A, RYBICKI L, BUKOWSKI R. Downregulation of topoisomerase IIβ in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest. Leukemia 2006; 20: 1809-1818.
32. FIEGL M, ZIMMERMANN I, LORENZ I, HIDDEMANN W, BRAESS J. In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia. Ann Hematol 2008; 87: 27-33.
33. DIFFNER E, GAUFFIN F, ANAGNOSTAKI L, NORDGREN A, GUSTAFSSON B, SANDER B, GUSTAFSSON B, PERSSON JL. Expression of VEGF and VEGF receptors in childhood precursor B-cell acute lymphoblastic leukemia evaluated by immunohistochemistry. J Pediatr Hematol Oncol 2009; 31: 696-701.
34. VERSTOVSEK S, KANTARJIAN H, MANSHOURI T, CORTES J, GILES FJ, ROGERS A, ALBITAR M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 2002; 99: 2265-2267.
35. GIGLIO AD, O'BRIEN S, FORD RJ, MANNING J, SAYA H, KEATING M, JOHNSTON D, CHAMONE DF, DEISSEROTH AB. Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL). Leukem Lymph 1993; 10: 265-271.
36. KIJOWSKI J, BAJ-KRZYWORZEKA M, MAJKA M, RECA R, MARQUEZ LA, CHRISTOFIDOU-SOLOMIDOU M, JANOWSKAWIECZOREK A, RATAJCZAK MZ. The SDF-1-CXCR4 Axis Stimulates VEGF Secretion and Activates Integrins but does not Affect Proliferation and Survival in Lymphohematopoietic Cells. Stem Cells 2001; 19: 453-466.
37. NOZAWA F, ITAMI A, SARUC M, KIM M, STANDOP J, PICHA KS, COWAN KH, POUR PM. The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth. Pancreas 2004; 29: 45-52.
38. RICCIONI R, PASQUINI L, MARIANI G, SAULLE E, ROSSINI A, DIVERIO D, PELOSI E, VITALE A, CHIERICHINI A, CEDRONE M. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005; 90: 612-624.